Carlos V. Paya, M.D., Ph.D.

Carlos V. Paya, M.D., Ph.D. Director

Dr. Paya has been a director since May 2019 and is a member of Mallinckrodt’s Portfolio Committee.

He is also a member of the board of BIO (Biotechnology Innovation Organization), and a board member and chair of the nominating and governance committee for Fludigm Corporation, a biotechnology tools provider.

Dr. Paya recently stepped down as the president, chief executive officer and board member of Immune Design Corp., a late-stage immunotherapy company, following its acquisition by Merck. He previously served as president of Elan Pharmaceuticals, and spent a number of years with Eli Lilly and Co. in discovery research, clinical development leadership roles, most recently global leader of the diabetes and endocrine franchise. Prior to his industry roles, Dr. Paya spent nearly a decade at the Mayo Clinic-Rochester, including his role as professor of medicine, immunology and pathology, and vice dean of the clinical investigation program.

After receiving his medical and doctorate degrees from the Universidad Complutense of Madrid Medical School, Dr. Paya completed his specialty training in Internal Medicine, Infectious Diseases and Immunology at the Mayo Graduate School of Medicine. He was a research scientist in a post-doctoral position at Institute Pasteur in Paris and completed the advanced management program at the University of Chicago’s Booth School of Business.